Sarep­ta's con­fir­ma­to­ry Duchenne tri­al fails to meet end­point, com­pli­cat­ing fu­ture for con­tro­ver­sial drug

Sarep­ta and Roche’s con­fir­ma­to­ry study for a Duchenne gene ther­a­py failed to hit its pri­ma­ry end­point, com­pli­cat­ing plans to con­vert the drug’s la­bel in­to a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER